Physician profile
John W Whelan
NPI 1932202116
$1,465.03
in general payments reported to CMS, 2019-2025
18 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $174 · 2022: $41.64 · 2023: $101 · 2024: $243 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.63 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $382.31 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $289.21 | 2019-2025 | Repatha, Evenity, Otezla |
| Janssen Pharmaceuticals, INC | $163.84 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.76 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $90.18 | 2019-2025 | Airsupra |
| Lilly USA, LLC | $73.25 | 2019-2024 | Jardiance, Zepbound |
| Amarin Pharma, INC. | $72.02 | 2019-2020 | |
| Dexcom, INC. | $69.53 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $34.50 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $31.29 | 2019-2020 | |
| Pfizer INC. | $29.55 | 2019-2022 | |
| Gilead Sciences, INC. | $28.20 | 2024 | |
| Allergan, INC. | $20.36 | 2019 | |
| Glaxosmithkline, LLC. | $18.04 | 2020 | |
| Bausch Health US, LLC | $16.08 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.96 | 2025 | |
| Merck Sharp & Dohme LLC | $12.10 | 2019 | |
| Travere Therapeutics, INC. | $9.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Whelan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.